News | May 03, 2023
Astec LifeSciences FY23 PAT declines to Rs. 25.6 Cr
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
The business and product range of Ipca and that of Unichem complements each others business and product range
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
Licences should enable potentially millions of people living in areas most impacted by HIV to access this innovative prevention medicine through low-cost generic manufacturers
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
PM emphasises the need to enhance lab surveillance & testing of all Severe Acute Respiratory Illness (SARI) cases & ramp up genome sequencing
The Indian government will float a global tender in April 2023 to procure HPV vaccines.
Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies
The business serves the healthcare and laboratory sectors on the west coast of the United States.
Subscribe To Our Newsletter & Stay Updated
